These data imply that the inflammasome is not triggered in these clinical conditions, probably explaining the discrepancy in literature and the unsuccessful randomized clinical trials performed on stable COPD patients subjected to canakinumab (monoclonal antibody against IL-1β) or an anti-P2X7 antagonist (1). The gene discussed is P2RX7; the disease is chronic obstructive pulmonary disease.